Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma

Genes Chromosomes and Cancer

Volumn 48, Issue 12, 2009, Pages 1057-1068

  Lu, Chang Yi ^a,b   Hsieh, Sen Yung ^c   Lu, Yen Jung ^a   Wu, Chi Sheng ^d   Chen, Lih Chyang ^d   Lo, Shao Jung ^d   Wu, Cheng Tao ^a,b   Chou, Min Yuan ^b   Huang, Tim Hui Ming ^e   Chang, Yu Sun ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID RECEPTOR 1; BISULFITE; DOXORUBICIN; FLUOROURACIL; KALLIKREIN; KALLIKREIN 10; MESSENGER RNA; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXICITY; DIFFERENTIAL METHYLATION HYBRIDIZATION; DNA HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; DRUG SENSITIVITY; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; COLONY-FORMING UNITS ASSAY; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 70350236515     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20708     Document Type: Article

References (33)

1. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M. 2006. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 103:8822-8827. (Pubitemid 43878103)
2. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, Martinez de Pancorboa M. 2004. P14ARF gene alterations in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 16:19-26.
3. Borgono CA, Diamandis EP. 2004. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4:876-890. (Pubitemid 39472954)
4. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG. 2003. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9:2912-2919. (Pubitemid 36993249)
5. Christman JK. 2002. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21:5483-5495.
6. De Zhu J. 2005. The altered DNA methylation pattern and its implications in liver cancer. Cell Res 15:272-280. (Pubitemid 41642883)
7. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H. 2003. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106:334-341. (Pubitemid 36870393)
8. Farazi PA, DePinho RA. 2006. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 6:674-687. (Pubitemid 44286000)
9. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. 1998. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58:4782-4786. (Pubitemid 28503667)
10. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, Tian H, Ling L. 2004. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429:188-193. (Pubitemid 38656195)
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826. (Pubitemid 26296693)
12. Huang W, Zhong J, Wu LY, Yu LF, Tian XL, Zhang YF, Li B. 2007. Down regulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett 251:78-85. (Pubitemid 46589767)
13. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, Hirashima N, Orito E, Osada H, Ueda R, Guo Y, Chen X, Issa JP, Sekido Y. 2007. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 37:974-983.
14. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. 2003. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163:1371-1378. (Pubitemid 37175085)
15. Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, Wazer DE, Band V. 2001. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res 61:8014-8021. (Pubitemid 33049395)
16. Liedtke C, Zschemisch NH, Cohrs A, Roskams T, Borlak J, Manns MP, Trautwein C. 2005. Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology 129:1602-1615. (Pubitemid 41597400)
17. Liu WJ, Wang L, Wang JP, Li JQ, Zhang CQ, Zheng L, Yuan YF. 2006. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma]. Ai Zheng 25:696-700.
18. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF. 2001. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61:8659-8663. (Pubitemid 34013873)
19. Matsukura S, Soejima H, Nakagawachi T, Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y, Sekiguchi M, Mukai T. 2003. CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer 88:521-529. (Pubitemid 36363361)
20. Matsumoto K, Imagawa S, Obara N, Suzuki N, Takahashi S, Nagasawa T, Yamamoto M. 2006. 2-Oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia-inducible factor-1α and inhibits angiogenesis. J Cell Physiol 209:333-340. (Pubitemid 44484623)
21. Meiers I, Shanks JH, Bostwick DG. 2007. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: Review 2007. Pathology 39:299-304. (Pubitemid 46897603)
22. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. 2008. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47:908-918.
23. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Barrios M, Andreu EJ, Prosper F, Heiniger A, Torres A. 2004. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 18:362-365. (Pubitemid 38240058)
24. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K. 2003. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63:8606-8613. (Pubitemid 38064034)
25. Shen L, Fang J, Qiu D, Zhang T, Yang J, Chen S, Xiao S. 1998. Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. Hepatogastroenterology 45:1753-1759. (Pubitemid 28515195)
26. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. 2007. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67:11335-11343. (Pubitemid 350248560)
27. Strathdee G, Brown R. 2002. Aberrant DNA methylation in cancer: Potential clinical interventions. Expert Rev Mol Med 2002:1-17.
28. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. 2002. Mutational spectrum of b-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21:4863-4871. (Pubitemid 34879463)
29. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R, Huang TH. 2002. Methylation microarray analysis of latestage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8:2246-2252. (Pubitemid 34753597)
30. Xiong Z, Laird PW. 1997. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25:2532-2534. (Pubitemid 27303718)
31. Xue KX. 2005. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis]. Ai Zheng 24:757-768.
32. Yang B, Guo M, Herman JG, Clark DP. 2003. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163:1101-1107. (Pubitemid 37040145)
33. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. 2003. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 13:319-333. (Pubitemid 43231848)